Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals (Nasdaq: XFOR) announced that its management team will participate in the Guggenheim Second Annual Healthcare Innovation Conference in Boston on November 10–12, 2025. The company will host a fireside chat on November 10 at 8:30 a.m. ET and will be available for one-on-one investor meetings. A live webcast of the fireside chat will be available on the company’s Investors > Events and Presentations page, with a replay accessible for 30 days after the event. For more information, visit investors.x4pharma.com.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q3 2025 results and a corporate update focused on advancing the 4WARD Phase 3 trial of mavorixafor for chronic neutropenia. The company completed two financings totaling $240.3M and said cash runway now extends to the end of 2028, supporting trial completion, a potential sNDA filing and a possible 2028 launch if successful. Operational changes include a 50% workforce reduction (estimated $13M annualized savings), deprioritization of WHIM commercialization, promotion of John Volpone to COO, and an increased 4WARD enrollment target of 176 patients with completion expected in Q3 2026.
Q3 net product sales were $1.6M, Q3 net loss was $29.8M (EPS -$0.69), and cash, cash equivalents and short-term investments were $122.2M as of Sept 30, 2025.
X4 Pharmaceuticals (Nasdaq: XFOR) closed an underwritten public offering on October 27, 2025, selling 52,844,000 common shares including the full exercise of a 6,984,000-share underwriter option at $2.90 per share.
The company also issued pre-funded warrants for up to 700,000 shares at a public price of $2.899 each, exercisable immediately at $0.001 per share. Aggregate gross proceeds were approximately $155.3 million before underwriting discounts, commissions and offering expenses. Total shares outstanding after the offering were 79,214,708. Joint bookrunners were Leerink Partners, Stifel and Guggenheim Securities.
X4 Pharmaceuticals (Nasdaq: XFOR) priced an underwritten public offering of 45,860,000 shares at $2.90 per share and up to 700,000 pre-funded warrants at $2.899 each (exercise price $0.001). The offering is expected to generate approximately $135 million in gross proceeds before underwriting discounts, commissions and expenses and is expected to close on October 27, 2025, subject to customary conditions.
X4 granted underwriters a 30-day option to buy up to an additional 6,984,000 shares. Net proceeds will fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders and support general corporate purposes.
X4 Pharmaceuticals (Nasdaq: XFOR) commenced an underwritten public offering on October 23, 2025 of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities. The offering is subject to market and other conditions and may not be completed.
Use of proceeds is stated as funding the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, plus general and administrative expenses, capital expenditures, working capital and other corporate purposes. Leerink Partners, Stifel and Guggenheim are joint bookrunning managers. A shelf registration became effective on August 24, 2023.
X4 Pharmaceuticals (NASDAQ:XFOR) announced a major strategic restructuring aimed at streamlining operations and focusing on its 4WARD Phase 3 trial in chronic neutropenia patients. The restructuring includes a 50% workforce reduction, expected to generate $13 million in annual cost savings.
Key management changes include John Volpone's appointment as COO while retaining his President role, and Dr. Adam Craig (Executive Chairman) taking oversight of clinical development. Several executives, including the Chief Legal Officer, former COO, Chief Commercial Officer, and Chief Medical Officer, will be departing the company.
[ "Expected annual cost savings of $13 million from restructuring", "Streamlined management structure with focused leadership", "Strategic focus on advancing 4WARD Phase 3 trial in chronic neutropenia" ]X4 Pharmaceuticals (Nasdaq: XFOR) has announced significant inducement grants to three new executive officers under its 2019 Inducement Plan. The grants include stock options for 12.7 million shares issued on August 12, 2025, and additional 1.4 million shares on August 14, 2025.
The initial grants were distributed among Dr. Adam Craig, John Volpone (4.25 million shares each), and David Kirske (2.83 million shares) at $1.42 per share. Additional grants were issued at $3.14 per share following X4's $85 million private placement. The options feature varying vesting schedules over 18-36 months, subject to performance conditions and continued employment.
X4 Pharmaceuticals (NASDAQ:XFOR) has successfully closed an upsized $85 million private placement, exceeding the initially announced $60 million offering. The financing includes 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares.
The offering was led by Coastlands Capital with participation from notable investors including Empery Asset Management, Bain Capital Life Sciences, and NEA. The proceeds will support the continued development of mavorixafor for potential approval in chronic neutropenia and its commercialization in WHIM syndrome.
X4 Pharmaceuticals (NASDAQ: XFOR) has announced a significant $60 million PIPE financing led by Coastlands Capital, with support from Bain Capital Life Sciences and NEA. The financing involves issuing 11,040,776 shares of common stock at $1.42 per share and pre-funded warrants for up to 31,234,731 shares.
Concurrent with the financing, X4 has undergone major leadership changes. Dr. Adam Craig has been appointed as Executive Chairman, John Volpone as President, and David Kirske as CFO, replacing former CEO Paula Ragan and CFO Adam Mostafa. The new management team, previously from CTI BioPharma, brings extensive experience in operational turnarounds and life sciences.
The proceeds will support the development of mavorixafor for chronic neutropenia treatment and its commercialization for WHIM syndrome. The company's Phase 3 4WARD study is currently ongoing.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
